Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight

Over 65 pharmaceutical companies are advancing 75+ pipeline COPD drugs, with the treatment landscape evolving beyond traditional bronchodilators toward targeted biologics and anti-inflammatory therapies. Recent clinical trial successes include AstraZeneca's tozorakimab meeting primary endpoints in Phase III trials, and multiple companies progressing novel candidates through various development stages.

04/23/2026, 1:00 PM • GlobeNewswire

Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight

The severe asthma drug development pipeline shows strong momentum with 30+ pharmaceutical companies actively developing 35+ pipeline therapies across various clinical stages. Key players including AstraZeneca, Generate Biomedicines, GSK, and others are advancing promising candidates targeting thymic stromal lymphopoietin inhibitors and interleukin pathways. Recent approvals and positive trial results, including GSK's Exdensur and Upstream Bio's verekitug, demonstrate progress in addressing this unmet medical need.

04/07/2026, 1:00 PM • GlobeNewswire

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

Sanofi reported positive Phase 2 data for lunsekimig, its bispecific antibody targeting TSLP and IL-13. The drug met primary endpoints in asthma and nasal polyp studies with significant improvements in exacerbations and polyp size. However, an atopic dermatitis trial missed its primary endpoint, though secondary measures showed some clinical activity. The drug demonstrated a favorable safety profile across all studies.

04/07/2026, 7:02 AM • Benzinga

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Upstream Bio announced additional analyses from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP). The drug met its primary endpoint with a nasal polyp score reduction of -1.95 (p < 0.0001) and reduced the need for surgery or systemic corticosteroids by 76% compared to placebo. The company plans to initiate Phase 3 trials in CRSwNP and severe asthma following regulatory interactions.

03/01/2026, 9:45 AM • GlobeNewswire

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Upstream Bio announced it will present additional efficacy analyses from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps at the AAAAI Congress 2026. The presentation will include new analyses assessing verekitug's efficacy with adjustment for concomitant rescue therapy use. Verekitug is a novel monoclonal antibody targeting the TSLP receptor and is currently in development for multiple inflammatory diseases including severe asthma and COPD.

02/26/2026, 7:00 AM • GlobeNewswire

Upstream Bio to Participate in Upcoming March Investor Conferences

Upstream Bio announced that CEO Rand Sutherland will participate in two major investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference on March 4 and the Leerink Partners Global Healthcare Conference on March 9. The company is developing verekitug, a TSLP receptor antagonist in Phase 2 trials for severe respiratory disorders including chronic rhinosinusitis with nasal polyps, severe asthma, and COPD.

02/25/2026, 7:00 AM • GlobeNewswire

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Upstream Bio announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, a TSLP receptor antagonist for severe asthma treatment, on February 11, 2026. The trial evaluated 478 patients across multiple dosing regimens in a randomized, double-blind, placebo-controlled study.

02/10/2026, 6:00 PM • GlobeNewswire

Upstream Bio to Participate in Upcoming November Investor Conferences

Upstream Bio, a clinical-stage biotechnology company, will participate in multiple investor conferences in November 2025, presenting its research on verekitug, a potential treatment for inflammatory respiratory diseases.

10/31/2025, 7:00 AM • GlobeNewswire